+86-27-65522453 sales@sun-shinechem.com


Catalog No.: 51802
Cas No.: 1616632-77-9
Purity : 98% 
51802 - TIC10 | CAS 1616632-77-9

Catalog number : 51802

CAS number : 1616632-77-9

Molecular Formula : C24H26N4O 

Molecular Weight : 386.49 

Iupac Chemical Name : 2,4,6,7,8,9-hexahydro-4-((2-methylphenyl)methyl)-7-(phenylmethyl)imidazo(1,2-a)pyrido(3,4-e)pyrimidin-5(1h)-one 

Smile : CC1=C(C=CC=C1)CN1C=2N(C3=C(C1=O)CN(CC3)CC3=CC=CC=C3)CCN2


PackagingPriceAvailabilityPurityEstimated Shipping Time
Request Bulk Quote Download MSDSTel:+86-27-65522453 | Email:sales@sun-shinechem.com
Molecular FormulaC24H26N4O 
Molecular Weight386.49 
AppearanceLight-yellow solid 
Solubility2mg/ml in DMSO 
Storage3 years -20ºCpowder 6 months-80ºCin solvent 
Shipping ConditionShipped under ambient temperature 

TIC10 inactivates Akt and ERK to induce TRAIL through Foxo3a, possesses superior drug properties: delivery across the blood-brain barrier, superior stability and improved pharmacokinetics. Phase 1/2.

1: Fang Z, Wang J, Clark LH, Sun W, Yin Y, Kong W, Pierce SR, West L, Sullivan SA, Tran AQ, Prabhu VV, Zhou C, Bae-Jump V. ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro. Am J Cancer Res. 2018 Aug 1;8(8):1551-1563. eCollection 2018. PubMed PMID: 30210923; PubMed Central PMCID: PMC6129479. 

 2: Bárány P, Oláh RS, Kovács I, Czuczi T, Szabó CL, Takács A, Lajkó E, Láng O, Kőhidai L, Schlosser G, Bősze S, Mező G, Hudecz F, Csámpai A. Ferrocene-Containing Impiridone (ONC201) Hybrids: Synthesis, DFT Modelling, In Vitro Evaluation, and Structure⁻Activity Relationships. Molecules. 2018 Sep 3;23(9). pii: E2248. doi: 10.3390/molecules23092248. PubMed PMID: 30177664.

 3: Ralff MD, Lulla AR, Wagner J, El-Deiry WS. ONC201: a new treatment option being tested clinically for recurrent glioblastoma. Transl Cancer Res. 2017 Oct;6(Suppl 7):S1239-S1243. doi: 10.21037/tcr.2017.10.03. PubMed PMID: 30175049; PubMed Central PMCID: PMC6117120.  

4: Karpel-Massler G, Siegelin MD. TIC10/ONC201-a potential therapeutic in glioblastoma. Transl Cancer Res. 2017 Dec;6(Suppl 9):S1439-S1440. doi: 10.21037/tcr.2017.10.51. PubMed PMID: 30148071; PubMed Central PMCID: PMC6108585. 

5: Chari A, Barlogie B. Imipridone ONC201: combination therapy in hematologic malignancies. Cell Cycle. 2018;17(16):1947-1948. doi: 10.1080/15384101.2018.1490861. Epub 2018 Sep 11. PubMed PMID: 29929441; PubMed Central PMCID: PMC6224273. 

 6: Romaguera JE, Lee HJ, Tarapore R, Prabhu V, Allen J, Schalop L, Zloza A, Ok CY, Sadimin ET, Schenkel J, Badillo M, Wang M. Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment. Br J Haematol. 2018 May 8. doi: 10.1111/bjh.15271. [Epub ahead of print] PubMed PMID: 29740811. 

7: Greer YE, Porat-Shliom N, Nagashima K, Stuelten C, Crooks D, Koparde VN, Gilbert SF, Islam C, Ubaldini A, Ji Y, Gattinoni L, Soheilian F, Wang X, Hafner M, Shetty J, Tran B, Jailwala P, Cam M, Lang M, Voeller D, Reinhold WC, Rajapakse V, Pommier Y, Weigert R, Linehan WM, Lipkowitz S. ONC201 kills breast cancer cells in vitro by targeting mitochondria. Oncotarget. 2018 Apr 6;9(26):18454-18479. doi: 10.18632/oncotarget.24862. eCollection 2018 Apr 6. PubMed PMID: 29719618; PubMed Central PMCID: PMC5915085.

1616632-77-9 - Request Bulk Quote

1616632-77-9 - Request Bulk Quote